A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer
- 1 August 2004
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 94 (2) , 442-448
- https://doi.org/10.1016/j.ygyno.2004.05.041
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- Adenovirus-Mediated p53 Growth Inhibition of Ovarian Cancer Cells Is Independent of Endogenous p53 StatusGynecologic Oncology, 1999
- Growth Inhibition of Human Cervical Cancer Cells with the Recombinant Adenovirusp53 in VitroGynecologic Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Adenovirus-Based p53 Gene Therapy in Ovarian CancerGynecologic Oncology, 1995
- Stable Expression of the Wild-Typep53Gene in Human Lung Cancer Cells after Retrovirus-Mediated Gene TransferHuman Gene Therapy, 1993
- Intraperitoneal chemotherapy: Analysis of complications with an implanted subcutaneous port and catheter systemGynecologic Oncology, 1991
- Long-term access to the peritoneal cavity in ovarian cancer patientsGynecologic Oncology, 1989
- Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosisGynecologic Oncology, 1986
- Catheter complications associated with intraperitoneal chemotherapyGynecologic Oncology, 1986